Skip navigation

Clarity, Guiding Strategies and Industry Benchmarking Amid Program Change and Policy Uncertainty

May 20-22, 2019
  • Orlando, FL

BREAKING NEWS IMPACTING MANUFACTURERS: The Administration has signed into law significant, targeted amendments to the Medicaid Drug Rebate Program statute. Section 6 of the Medicaid Services Investment and Accountability Act of 2019 takes aim at drug misclassification in the MDRP with new enforcement and civil monetary penalties for those improperly claiming noninnovator status. Join us in May to proactively prepare.

In light of recent CMS rule changes and President Trump’s America First Blueprint, MDRP and GP execs are asking many questions about the future of Medicaid and evolving government pricing and reporting requirements. Effectively navigating the political and regulatory landscape while effectively managing the increasing demands of government price reporting is critical to overall success.

CBI’s 21st Annual Medicaid and Government Pricing Congress is built off of the changing dynamics within the pharmaceutical landscape and arms attendees with action-oriented discussions and actionable takeaways on a full range of content including state pricing transparency, Medicare reform, value-based frameworks, 340B, supplemental rebates, reasonable assumptions and much more.

Session Spotlight

GP in the Upside-Down —
Unpack the Pricing Implications of a World Without PBM/Payor Rebates

John Shakow
King & Spalding

Conference Co-Chairs graphic

Political & Legislative Trends State & Fed Transparency Regulations
340B Guidance Civil Monetary Penalties Changes to Medicare
State Invoicing and Disputes Contracting Strategies with PBMs
Value-Based Frameworks Analytics and Technology
Bona Fide Service Fees Gross-to-Net and Accruals


Previous Attendee Acclaim quote graphic

2018 Congress Highlights:

Reach Out to the #OrlandoMedicaid Team to Get Involved:
Medicaid team contacts
Stay Connected and Join the Conversation: